They will speak at BioFIT 2018:
- Jan Adams, Managing Director, EMBL Ventures (DE)
- Anjan Aralihalli, Venture Partner, CTI Life Sciences Fund II (CA)
- Caroline Barelle, CEO, Elasmogen (UK)
- Yann Barrault, Head of Business Development & Licensing, SATT Grand Centre (FR)
- Jean-Charles Brosse, Partner Healthcare & Life Sciences, Positive Capital (FR)
- Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
- Lucie Ellis, Senior Editor, Pharma Intelligence | Informa (UK)
- Juan Garcia, CEO, BioSeed Capital (ES)
- George Hoffman, Co-founder and CEO, Network Immunology (US)
- Adrian Ibrahim, Head of Technology Transfer, Wellcome Sanger Institute (UK)
- Steven J. Klein, Vice President, Business Development, IRICoR – Institute for Research in Immunology and Cancer-Commercialization of Research (CA)
- Peter Leonardi, CEO, OmniCyte (US)
- Michael Motz, CBO, NETRIS Pharma (FR)
- Michael L. Salgaller, Supervisor, Invention Development and Marketing Unit, National Institutes of Health (NIH) | National Cancer Institute (NCI) | Technology Transfer Center (US)
- Bernd Stowasser, Head of Alliance Management Germany & Global Public Private Partnerships, Sanofi (DE)
- Jonathan Tobin, Investment Director, Arix Bioscience (UK)
- Ewa Truchanowicz, Life Sciences Lead, University of Birmingham Enterprise (UK)
- Bram Vanparys, Investment Director, MS Ventures (NL)
|
|
